Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives Consensus Rating of “Moderate Buy” from Analysts

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has received a consensus recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $31.3333.

GLUE has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d)” rating on shares of Monte Rosa Therapeutics in a report on Monday, December 29th. Piper Sandler reissued an “overweight” rating and issued a $37.00 price objective (up previously from $27.50) on shares of Monte Rosa Therapeutics in a report on Wednesday. Wedbush restated an “outperform” rating and set a $37.00 target price on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 7th. Guggenheim lifted their price target on shares of Monte Rosa Therapeutics from $16.00 to $34.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Finally, Zacks Research raised Monte Rosa Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 6th.

Insider Activity at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, CEO Markus Warmuth sold 5,466 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $23.49, for a total value of $128,396.34. Following the transaction, the chief executive officer directly owned 618,937 shares of the company’s stock, valued at $14,538,830.13. This trade represents a 0.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Tema Etfs LLC acquired a new stake in shares of Monte Rosa Therapeutics during the 4th quarter valued at $388,000. Nisa Investment Advisors LLC increased its holdings in Monte Rosa Therapeutics by 16.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after purchasing an additional 451 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in Monte Rosa Therapeutics by 9.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 26,955 shares of the company’s stock valued at $423,000 after purchasing an additional 2,358 shares during the last quarter. Mayflower Financial Advisors LLC acquired a new stake in shares of Monte Rosa Therapeutics during the fourth quarter valued at about $157,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Monte Rosa Therapeutics during the fourth quarter valued at about $271,000. Institutional investors and hedge funds own 79.96% of the company’s stock.

Monte Rosa Therapeutics Stock Down 1.5%

Shares of NASDAQ:GLUE opened at $23.71 on Friday. Monte Rosa Therapeutics has a 12-month low of $3.50 and a 12-month high of $25.77. The business has a 50 day moving average of $17.17 and a 200-day moving average of $10.45. The stock has a market cap of $1.54 billion, a PE ratio of 74.10 and a beta of 1.60.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its earnings results on Thursday, November 6th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.06. The company had revenue of $12.77 million for the quarter, compared to analyst estimates of $7.37 million. Monte Rosa Therapeutics had a return on equity of 8.28% and a net margin of 11.54%. Equities research analysts expect that Monte Rosa Therapeutics will post -1.49 earnings per share for the current year.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.